The pharmacy inquiry will explore issues impacting different types of pharmacy, with a particular focus on community, primary care and hospital pharmacy
services.
It will also consider current challenges around funding, workforce and the digital infrastructure.
Planned developments within the profession will enable future pharmacists to be independent prescribers from day one of registration, giving them a greater role
within primary care teams.
Health and Social Care Committee Chair Steve Brine MP said: "It is clear that pharmacy has a central role to play in the future of the NHS. With a greater focus on
personalised and patient-centred healthcare, we will be asking what more must be done to make sure that the profession is in the best shape to meet demand.
"Better use of the pharmacy workforce would reduce pressures on general practice and hospitals. However, this will not happen without a planned workforce with the
funding, supervision and training to support it.
"At the end of the inquiry, the committee will be making recommendations to the government on what action needs to be taken to ensure the potential of pharmacy is
realised.
Integration of primary and community care is key to health service improvement - Lords Committee has said in a new report published on 15 December.
The report highlighted the need for better staff training, improved data-sharing, flexible healthcare structures and collaboration across different professions in
the healthcare system to support more integrated care.
Royal Pharmaceutical Society (RPS) England has welcomed the report, and highlighted the important role pharmacy teams can play in improving patient care.
Tase Oputu, Chair of RPS England Pharmacy Board, said: "Pharmacists and pharmacy teams play a vital role in supporting more integrated care, working with
multidisciplinary teams across the health service.
During the coronavirus pandemic many people found themselves working from home, and this has continued to some extent in many businesses. A change in working
environment can bring challenges, one of which can be joint pain and discomfort.
Imagine you have gone from a busy office environment, meeting in boardrooms and visiting the canteen for a coffee, to working at home on your dining room table,
walking several feet to get a cup of tea and sitting back down again, this change in surroundings can have an impact on your joints.
Community pharmacists can be a source of knowledge to help individuals that may be suffering from joint complaints, this may be from the above scenario or just
general aches and pains that come from an office based role.
Firstly, it's important for us to know the effects of sitting down at a desk all day (not a scenario I'm sure many community pharmacists experience daily):
Back pain - is one of the most common complaints. This can be caused by bad posture while sitting too high, too low, or hunched over. While this may present as
just a soreness or discomfort, if not rectified and/or accessed this can lead to some serious health issues such as spinal compression, sciatica or spinal stenosis.
The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered
pharmacies are governed.
The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was
delayed due to Brexit and the Covid-19 pandemic.
The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core
purpose of the Responsible Pharmacist and Superintendent Pharmacist roles.
It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.
UK-based consumer health company Kenvue has developed a series of tools and materials to support healthcare professionals - including pharmacy teams - with
their conversations with smokers on their quit journey.
This is part of their newly launched Smokefree Families initiative, which aims to help reduce the number of smoking households with children in England.
Kenvue believes that pharmacists and their teams are vital to the success of this initiative, as they play a crucial role in supporting smokers in their quit
journey.
"As trusted sources of support and advice to families across the country, we firmly believe that community pharmacy teams are crucial to the success of our Smokefree
Families initiative," Manoj Raghunandanan, Area Managing Director, Northern Europe at Kenvue, told Pharmacy Business.
"To support them, we've created a series of tools and materials that can help pharmacists and other healthcare professionals tackle sensitive conversations with
new and expectant parents, their partners and support networks, and ultimately motivate them on their quit journey."
The Royal Pharmaceutical Society (RPS) and the charity Marie Curie have developed a consultation on 'professional standards for palliative and end of life care
for community pharmacy'.
The consultation will be open for four weeks for community pharmacists, organisations with a role in community pharmacy or palliative/end of life care, or patients
or carers with first-hand experience of palliative and end of life care to share their views until 1st December 2022.
Through this consultation, Society aims to that ensure the standards are clear, relevant, current, and fit for purpose from the perspective of the community pharmacy
team, the wider health team and patients/carers.
"The final standards will be published in 2023 and will help community pharmacies across the UK to self-assess and continuously improve their palliative, end of
life and bereavement care," said RPS.
Wes Streeting MP has been appointed Secretary of State for Health and Social Care in the new Labour Government.
The Ilford North MP will now take on the critical role of overseeing the National Health Service (NHS) and implementing Labour's ambitious health agenda.
At the core of the Labour Party's healthcare reform manifesto is enhancing accessibility to primary and community healthcare. This involves implementing a
'Community Pharmacist Prescribing Service,' to empower pharmacists with independent prescribing rights where clinically suitable.
This initiative aims to alleviate the strain on GP practices and enhance service accessibility.
Additionally, the manifesto proposes piloting Neighbourhood Health Centres, to integrate various healthcare services -such as family doctors, district nurses,
and mental health specialists under one roof.
The Pharmacy Supervision Practice Group held its second meeting to discuss the future modelling of pharmacy practice.
Some of the leading bodies from the community pharmacy sector have joined the group. The members explored themes centred around accountability, delegation and
responsibility.
The session included a wide-reaching discussion, including what future guidance might look like and the continued patient access to the pharmacist through a
comprehensive, accessible and equitable community pharmacy offer.
Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia, said: "The primary objective of the group is to
develop a co-designed and co-produced solution that will not only enhance the patient experience within community pharmacy practice, but that will enable the
community pharmacy workforce to maximise role and professional skills.
"At its second meeting, the group was unanimous that any changes in the delegation, responsibility and accountability space should be in the patient interest,
distil confidence for patients and ensure that community pharmacy remains accessible and equitable."
The National Pharmacy Association (NPA) highlighted the role played by community pharmacies during pandemic to provide urgent care and vital support to people
with long-term medical conditions at its opening remark in the Covid-19 public inquiry held on Tuesday (28 February).
NPA is the core participant in the Covid-19 public inquiry. lawyer Brian Stanton made an opening statement on the NPA's behalf which focused on three areas- health
inequalities and the needs of vulnerable patients; the impact of medicine shortages and medicine price increases and the challenge that community pharmacy faced in
responding to the pandemic and maintaining patient services following long-term under investment.
Stanton said: "The UK's community pharmacies were on the frontline of efforts to limit the impact of coronavirus and to keep people well, and as well as handling a
massive increase in demand for healthcare advice and medicines, they also continued to provide urgent care and vital support to people with long-term medical
conditions.
"However, there are now very many at risk of closure during to underfunding and when the Inquiry comes to consider its recommendations the NPA would encourage
you [the presiding judge] to think about how resilience can be built into future plans."
The statement included a compelling account of the commitment typical of so many pharmacies during the pandemic - from husband and wife Pete and Sukhi Johal, both
NPA members and pharmacists, who co-own Calow Pharmacy in Chesterfield.
The Royal Pharmaceutical Society (RPS) Wales and the Association of the British Pharmaceutical Industry (ABPI) co-hosted a drop-in session to inform members
of the Senedd (MSs) about the action taken by pharmacists to make medicines use more sustainable.
At a 'drop-in' session the ABPI, RPS members and staff had the opportunity to speak to a number of MSs from all political parties.
"With medicines accounting for around 25 per cent of the NHS carbon emissions, conversations were based around the key recommendations to reverse this from the RPS'
policies on sustainability," said RPS.
The three key themes emphasised in all discussions were- the need to educate the public and change behaviours to avoid stockpiling medicines; How the clinical skills
of prescribing pharmacists can be used for appropriate de-prescribing and switching patients to low carbon options; and importance of tackling waste.
RPS Wales Director Elen Jones said: "It was fantastic to see how interested and engaged the politicians were around these important issues. By the end of our
conversations, they all clearly understood and supported the importance of pharmacy leadership in this area, as well as the need for the link between climate
change and medicines to be better understood by patients.
It's no secret that as pharmacists we are navigating a new and more demanding healthcare landscape. Our role has changed significantly since the start of the 21st century due to increased expectations from the public, advances in science and technology and changing workforce pressures.
The Community Pharmacy Contractual Framework for England has placed a higher focus on clinical service. In addition, the Covid-19 pandemic resulted in significant
acceleration in changing how we work day-to-day and the public perception of our role.
Community pharmacy owners and staff have been under relentless pressure for the last two years. Dispensing volumes are continually increasing but dispensing revenues
are being replaced by launching new services. We must find solutions to reduce the time it takes to dispense medication so we can focus on these new revenue generating services.
To not just succeed, but to thrive, it is becoming increasingly important to understand and embrace the technology available.
To help pharmacy owner to better understand the negotiating process, Community Pharmacy England (CPE) has published commentary and infographics.
"Our work to negotiate fair funding, as well as changes to NHS pharmacy services, with the Department of Health and Social Care (DHSC) and NHS England is a
crucial part of our role," said CPE.
"Understandably the sector is eagerly awaiting an update on the progress of the current negotiations on the Government's pledge to invest £645m in community
pharmacies and, as part of our ongoing efforts to improve transparency of our work, we have released materials to explain the negotiating process."
Negotiating Team Member Stephen Thomas - who joined the team this year - has written a blog about his experiences.
He has described both the complexity of the process and volume of work undertaken, and recognises the significance of his role on behalf of pharmacy owners across
the country.
Whilst speed is of the essence, even higher on the Negotiating Team's list of priorities is working through a large number of important questions - particularly
around the funding and logistics that need to be put in place.
The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards
a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with
community pharmacies playing a central role in facilitating access.
The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic
research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on
cannabis-based medicinal products (CBPMs).
The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists
and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is
a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.
The Royal Pharmaceutical Society (RPS) has appointed Professor Parastou Donyai as chief scientist. She will take up the role in June.
Parastou is a pharmacist with a PhD in pharmacy. She also has a postgraduate diploma in Psychological Research Methods as well as a degree in Psychology.
She is currently a professor of Social & Cognitive Pharmacy at the University of Reading and her research examines the psychology of medication use, discontinuation
and decision-making processes.
Prior to this, Parastou also spent more than five years as a senior lecturer in Pharmacy Practice at Kingston University and St. George's University of London. Her
longstanding research interest includes continuing professional development in pharmacy.
Commenting on her appointment, Parastou said: "It is a real privilege for me to be the Royal Pharmaceutical Society's next chief scientist.
"As a pharmacist, scientist and academic, I look forward to working with the Royal Pharmaceutical Society's members and key stakeholders to uphold the value of
science across the breadth of our profession."
The Pharmacists' Defence Association (PDA) has raised the issue faced by the pharmacy students on returning to in-person assessments while urging the
universities to take an empathetic approach in transition of online to in-person exams.
It was highlighted by the association that many student members were apprehensive about the return to in-person assessments. This is due to their continuing worry of Covid-19 transmissions and anxiety caused by changing exam formats and procedures.
However, with the ease of Covid restrictions, now pharmacy schools are able to decide how exams are conducted but the PDA believes that they should communicate the
process to students in advance.
"A return to normal university life is considered to be beneficial to student health and well-being. In-person exams are an important part of preparing for students' future trainee assessment examinations, GPhC accreditation for pharmacy schools, and ensuring the integrity of exam results. As future healthcare professionals, face-to-face interaction is also an integral part of the role," said the PDA.
American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division.
Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division.
He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into
UK community pharmacies.
As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small
multiple operators) can be fully understood and supported.
Prime Minister Rishi Sunak was questioned whether he 'will take urgent action to prevent pharmacy closure'.
At Prime Minister's Questions (PMQs) in Parliament held on Wednesday (26 April) he replied, "we will continue to do everything we can to support community
pharmacies."
Labour MP for Knowsley and All-Party Pharmacy Group member, George Howarth said: "Given the chronic lack of capacity in the NHS, the Prime Minister will be aware
that community pharmacy can help deal with minor illnesses. But there is a problem on average 10 Pharmacy close every month in England."
Prime Minister was further asked "will he take urgent action to prevent further closing and commission a properly funded 'Pharmacy First' service for minor
illnesses?
Sunak replied: "I've been a wholehearted champion and believer in the role that community pharmacists can play. we want to make sure that they can do everything
to ease some of the pressures in primary care.
Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19.
"Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession.
She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy.
"They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."
Bas Vorsteveld, who was made vice president and general manager for Great Britain & Ireland (GBI) in November last year, is joined by Monica Michalopoulou as GBI marketing director and Onyeka Anugwom as GBI commercial excellence director GSK Consumer Healthcare.
He took over from Jonathan Workman, who held the position from 2018, and has now moved into the role of Business Unit general manager for Northern Europe.
Vorsteveld, who has 15 years' industry experience, played at major part in the merger of Novartis and GSK consumer healthcare businesses. Most recently, he held
the role of VP & head of commercial excellence EMEA LATAM at GSK Consumer Healthcare, where he spearheaded international sustainability initiatives.
Commenting on his new role, Vorsteveld said: "I am incredibly honoured to have been a part of GSK Consumer Healthcare's journey to date and it is our collective ambition to deliver better everyday health with humanity for our customers, with a laser focus on 'self-care'.
"The recent pandemic has shown us that healthcare matters more now than ever before for our consumers. We want to redefine the role that self-care plays in people's lives, because it can bring long-term benefits for individuals and society, and is a key component of a sustainable healthcare system.
In a surprising move that has divided the pharmacy profession, the General Pharmaceutical Council (GPhC) has sanctioned hundreds of pharmacies to allow
patients to self-select certain Pharmacy (P) medicines, a decision met with strong opposition from the Royal Pharmaceutical Society (RPS) as well as from the
Pharmacy Defense Association (PDA).
In a statement, RPS shared that at a board meeting held on 19th June, they expressed "disappointment" over what they described as a lack of prior consultation
and comprehensive communication from the GPhC regarding the implications of this policy shift.
They argue that allowing patients to self-select certain P medicines could potentially jeopardize established professional guidelines and compromise the role of
pharmacists in ensuring safe medication use.
"Enabled by the General Pharmaceutical Council, we understand that hundreds of pharmacies, from large multiples to small independents, have been approved by the
regulator to enable patients to self-select certain P medicines," the statement said.